Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | APP | P05067 | 6/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918290 | 1.00 | PTPN1 (0.43) | PTPN1APPPTGER4PTGER3PTGER2 | |
| SCHEMBL3917279 | 0.92 | PTPN1 (0.46) | PTPN1APPKDM4EGSK3BLMNA | |
| SCHEMBL4443447 | 0.92 | PTPN1 (0.46) | PTPN1APPKDM4EGSK3BLMNA | |
| SCHEMBL3918949 | 0.88 | PTPN1 (0.42) | PTPN1APPPTGER4PTGER3PTGER2 | |
| SCHEMBL3918955 | 0.88 | PTPN1 (0.42) | PTPN1APPPTGER4PTGER3PTGER2 | |
| SCHEMBL3919344 | 0.87 | KDM4E (0.53) | PTPN1APPPTGER4PTGER3PTGER2 | |
| SCHEMBL3919349 | 0.87 | KDM4E (0.53) | PTPN1APPPTGER4PTGER3PTGER2 | |
| SCHEMBL3916346 | 0.87 | PTPN1 (0.45) | PTPN1KDM4EGSK3BADAMTS5SIRT2 | |
| SCHEMBL3927794 | 0.85 | PTPN1 (0.38) | PTPN1APPKDM4EGSK3BLMNA | |
| SCHEMBL3927790 | 0.85 | PTPN1 (0.38) | PTPN1APPKDM4EGSK3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885APP 3032/4885PTGER4 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.